ATE307811T1 - Triazole für die behandlung von auf die modulation des dopamin d3 rezeptors ansprechende krankheiten - Google Patents
Triazole für die behandlung von auf die modulation des dopamin d3 rezeptors ansprechende krankheitenInfo
- Publication number
- ATE307811T1 ATE307811T1 AT04013358T AT04013358T ATE307811T1 AT E307811 T1 ATE307811 T1 AT E307811T1 AT 04013358 T AT04013358 T AT 04013358T AT 04013358 T AT04013358 T AT 04013358T AT E307811 T1 ATE307811 T1 AT E307811T1
- Authority
- AT
- Austria
- Prior art keywords
- dopamine
- acid addition
- receptor
- triazoles
- modulation
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- -1 triazole compounds Chemical class 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229940088353 Dopamine D3 receptor antagonist Drugs 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45551403A | 2003-06-05 | 2003-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307811T1 true ATE307811T1 (de) | 2005-11-15 |
Family
ID=33159567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04013358T ATE307811T1 (de) | 2003-06-05 | 2004-06-07 | Triazole für die behandlung von auf die modulation des dopamin d3 rezeptors ansprechende krankheiten |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1484330B1 (de) |
| JP (1) | JP2004359689A (de) |
| AT (1) | ATE307811T1 (de) |
| DE (1) | DE602004000158T2 (de) |
| TW (1) | TW200510395A (de) |
| WO (1) | WO2004108706A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2588457A1 (en) * | 2004-12-02 | 2006-06-08 | Abbott Gmbh & Co. Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| PA8802101A1 (es) * | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| EP3442955B1 (de) * | 2016-04-14 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Selektive d3-dopamin-rezeptor-agonisten und verfahren zu deren verwendung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4425144A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
-
2004
- 2004-06-04 JP JP2004167056A patent/JP2004359689A/ja not_active Withdrawn
- 2004-06-04 TW TW093116262A patent/TW200510395A/zh unknown
- 2004-06-07 DE DE602004000158T patent/DE602004000158T2/de not_active Expired - Lifetime
- 2004-06-07 AT AT04013358T patent/ATE307811T1/de not_active IP Right Cessation
- 2004-06-07 EP EP04013358A patent/EP1484330B1/de not_active Expired - Lifetime
- 2004-06-07 WO PCT/EP2004/006139 patent/WO2004108706A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004108706A1 (en) | 2004-12-16 |
| JP2004359689A (ja) | 2004-12-24 |
| DE602004000158T2 (de) | 2006-07-27 |
| TW200510395A (en) | 2005-03-16 |
| EP1484330B1 (de) | 2005-10-26 |
| EP1484330A1 (de) | 2004-12-08 |
| DE602004000158D1 (de) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE58699A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
| EP1857457A3 (de) | Benzimidazolderivate und ihre Verwendung als AII Rezeptor-Antagonist | |
| ATE13422T1 (de) | Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems. | |
| PE20040290A1 (es) | Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp | |
| DK0638071T3 (da) | Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR) | |
| EA023500B1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| CY1108367T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| JP2010536871A (ja) | スフィンゴシン−１−リン酸受容体アゴニストまたはアンタゴニスト生物学的活性を有するピロール化合物 | |
| MA27751A1 (fr) | 4-phényltétrahydroisoquinolines substituées, procédé de production de ces composés, utilisation de ces composés en tant que médicaments et médicament contenant de tels composés | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| ATE491453T1 (de) | Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges | |
| DE602004000158D1 (de) | Triazole für die Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
| DE60002558D1 (de) | Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B | |
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| DK1256581T3 (da) | Forebyggende eller terapeutiske midler til gastrisk eller ösofageal regurgitation | |
| ATE485291T1 (de) | Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs | |
| NO20015666D0 (no) | Umiddelbar frigivelses medisinske sammensetninger for oral anvendelse | |
| ATE522505T1 (de) | Benzensulfonamid-verbindungen zur behandlung von erkrankungen, die auf dopamin-d3- rezeptormodulation ansprechen | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| BRPI0606501A2 (pt) | derivados de ácido 3-fenilpropiÈnico, composto, composição farmacêutica que o contém, utilização do composto e método de tratamento e/ou profilaxia de enfermidades e condições mediadas por gama receptor ativado por proliferador de peroxissome (ppary) | |
| TW200633710A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |